Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLOG + FOLFIRINOX + GOFL appears to describe a multi-drug chemotherapy regimen composed of the drugs or regimens referred to as SLOG, FOLFIRINOX, and GOFL. - **FOLFIRINOX** is a well-documented combination chemotherapy regimen for advanced pancreatic cancer, consisting of four drugs: folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin. It acts by inhibiting DNA synthesis and repair and topoisomerase-mediated DNA processes, thereby killing rapidly dividing tumor cells[1][2][3][5][6]. - The compose and mechanisms of SLOG and GOFL are not defined in the sources found. However, these similarly-structured acronym regimens are often used in oncology to refer to specific combinations of chemotherapy agents. In general, combination chemotherapy regimens such as this are used to increase efficacy against cancer by employing several drugs with different mechanisms of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SLOG + FOLFIRINOX + GOFL.